Silfen, President and Chief Financial Officer of Cangen Biotechnologies, added, "The ability to work with Olympus in an effort to develop Cangen Biotechnologies' lung cancer detection technology to their high-throughput microarray platform improves substantially the likelihood for developing a commercially viable molecular diagnostic, early stage lung cancer test that can be offered at compelling prices.
Cangen Biotechnologies is based in Bethesda, MD, has laboratories in Rockville, MD and Baltimore, MD and has operations in Seoul, Korea.
The clinical relevancy of GliSODin has now been demonstrated in over 24 scientific studies and is exclusive to Millennium Biotechnologies, in the medical market, as the first orally effective, vegetarian form of superoxide dismutase.
Millennium Biotechnologies also owns the exclusive medical-market rights to GliSODin(R) (SOD/gliadin), the only orally effective form of the important antioxidant SOD (superoxide dismutase).
is a pioneer in the research and development of specialized nutritional products, namely Resurgex and Resurgex-plus, which are patented, multi-action, multi-component nutritional formulas designed to address the comprehensive needs of individuals struggling with immuno-compromised conditions such as HIV/AIDS as an adjunct to their medical care.
Pioneers Use of Defenzyme in Medical Nutrition for Immuno-Compromised Patients